Christopher James Frankenfield

Chief Operating Officer, Xilio Therapeutics, Inc.

Companies

Xilio Therapeutics, Inc.Chief financial officer Jan 3, 2025 to now¹
Xilio Therapeutics, Inc.Chief operating officer Aug 7, 2023 to Aug 6, 2024²

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Xilio Therapeutics, Inc. XLO24,766 shares³$206.3K at $8.33Jan 2, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

Jan 2, 2026Sold 7,030 shares at $0.64 of Xilio Therapeutics, Inc.³
Jan 1, 2026Exercised options 19,375 shares of Xilio Therapeutics, Inc.³
Jan 2, 2025Sold 6,954 shares at $0.98 of Xilio Therapeutics, Inc.⁴
Jan 1, 2025Exercised options 19,375 shares of Xilio Therapeutics, Inc.⁴

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARXilio Therapeutics, Inc., Chief financial officer
2
SEC EDGARXilio Therapeutics, Inc., Chief operating officer
3
SEC EDGARXilio Therapeutics, Inc. shares after the filing of Jan 2, 2026
4
SEC EDGARForm 4 filed Jan 3, 2025